Not a member? Register.
UltraShape® Contour I, ver 1
Launched in the UK in the summer of 2005, the UltraShape® (Contour I) device is marketed by its manufacturers (Ultrashape Inc.) as “the first proven non-invasive ultrasound solution for body contouring”. Since launch, the device has been modified and updated to make it more ergonomic and further improve outcomes.
The treatment is aimed as an alternative for women and men who want effective removal of excess fat cells without surgery, and focuses on the abdomen, inner and outer thighs (saddle bags) and flanks (love handles).
Unlike ultrasound-assisted liposuction techniques, it doesn’t require any incisions or surgery, and the body naturally rids itself of the unwanted fat content after treatment.
Focused ultrasound at an operation frequency of 200± 30KHz.
The UltraShape® treatment begins with the physician marking the treatment area or target zone (with a pen) and uploading it into the computer tracking system using coloured markers placed around the area. The physician then glides the transducer (the hand-held device that converts electrical energy into ultrasound energy) over the targeted zone, delivering short pulses of focused ultrasonic energy into the subcutaneous fat.
Each pulse breaks down the membranes of the fat cells, without impacting the blood vessels, nerves or other connective tissue, and the overlaying skin is also not damaged. By repeating the process, the device disrupts a layer of fatty tissue under the skin. A video camera monitors the positioning of the transducer and the person’s body, while the tracking system displays the areas already treated and indicates areas to be treated. The treatment session takes between ¾ and 1½ hours (depending on the area being treated) and afterwards you are able to return to your normal activities.
So what happens to the targeted fat? When treated by UltraShape, the membranes of the fat cells are disrupted and fat cell content, known as triglycerides, is dispersed into the fluid between the cells and then transported through the vascular (veins) and lymphatic systems to the liver. Once in the liver, there is no distinction between fat coming from the UltraShape treatment and fat originating from consumed food, and both are cleared from the liver via the body’s natural mechanisms.
Received CE mark approval in July 2005, as an “ultrasound system for non-invasive fat emulsification”.
US FDA approval is pending.
Trained members of the medical profession.
The Ultrashape® does not currently come under current Care Quality Commission legislation and can be used by a trained aesthetician with medical supervision.
The Ultrashape® treatment is aimed at the effective removal of excess fat cells without surgery, and focuses on the abdomen, inner and outer thighs (saddle bags) and flanks (love handles).
UltraShape® Contour I, ver 3
The results are seen gradually over a number of weeks, up to one month, as your body clears the fatty debris.
The manufacturers of the Ultrashape® device claim an average circumference loss of 2cm in one area after a single treatment session.
Results achieved with this procedure can be permanent as long as a sensible diet and exercise is maintained to avoid future weight gain.
There are very few documented side effects to date, although bruising is considered to be rare and if it occurs will be very mild, some redness and mild swelling may be noticed for a very short time post-treatment. Another rare possible side effect is a blister appearance in the treated area, which should heal in 1 – 2 days.
Women who are pregnant or breastfeeding.
Body areas with tattoos or significant moles present on the skin.
Those suffering from the following conditions:
The manufacturers claim a single treatment is enough, but more often than not, two treatment sessions per area is considered to be more appropriate by some practitioners; however it all depends on the amount of fat to be removed, and if it is felt that the final result after one treatment needs improving on or not.
Private costs for Ultrashape® treatment depends on the size of the area(s) being treated, and the number of areas that you have done in one treatment session, and can range from £300 – £800 per area, with an average cost of approximately £500.
Abdomen before Ultrashape® treatment .
Midline 96cm, Fat Thickness 5.0cm, BMI 25.3
3 months after Ultrashape® treatment.
Midline 93cm, Fat Thickness 2.5cm, BMI 25.3
Photographs courtesy of Consultant Plastic Surgeon, Mr Christopher Inglefield,
BSc, MBBS, FRCS (Plast) at London Bridge Plastic Surgery.
All before and after photographs are real patients, your results may differ.
What Happens to the Fat After Treatment With the UltraShape™ Device
Spencer Brown, Ph.D., Director of Plastic Surgery Research, UT Southwestern Medical Center, Dallas, USA
Non Invasive Ultrasonic Body Contouring – Initial Experience
Jacques Otto, M.D., Cosmedicate, London, UK
Contour I System: Clinical and Market Experience
Ami Glicksman, M.D.; Leonid, Kushkuley, PhD; Yoram Eshel, PhD
Congress: ISTU, Oxford, UK, August 2006
Contour I – Non invasive body contouring by focused ultrasound
A. Glicksman, M.D., Y. Eshel PhD
Congress: IMCAS, Paris, France, July 2006
The Combination of UltraShape Treatment with Adjuvant Fat Burning or Fat Mobilizing Solutions
Michael Franz, M.D., Luigi Polla, M.D.
Congress: 14th International Anti-Aging Congress, July 2006-08-30
Non- Invasive Body Contouring by Focused Ultrasound
Inglefield, Chris, M.D.
Congress: IMCAS, Paris, France, January 2006
Non-Invasive Body Contouring via Selective Mechanical Ultrasound Lipolysis
Otto, Jacques, M.D.
Congress: IMCAS, Paris, France, January 2006
Non Invasive Body contouring by Focused Ultrasound – The Ultrashape Solution
Ami Glicksman, M.D., Yoram Eshel, Ph.D.
Congress: Plastic Surgery, Paris, France, November 2005
Non-invasive body contouring by focused ultrasound – summary of clinical results from three clinical trials
Congress: ASPS, September 2005
Painless and Non-Invasive Body Contouring with the UltraShape™ Device (External Focused Ultrasound)
Steven Teitelbaum, M.D. FACS
Congress: BAAPS, UK, September 2005